Tina Sidoni

St. Salvatore Hospital
L'aquila, 67100, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Anthracycline-Free Neoadjuvant Pertuzumab-Trastuzumab-Taxane in Patients with HER2-Positive Early Breast Cancer: Hormone Receptor Status as a Key Determinant of Pathological Complete Response.

Anthracycline-Free Neoadjuvant Pertuzumab-Trastuzumab-Taxane in Patients with HER2-Positive Early Breast Cancer: Hormone Receptor Status as a Key Determinant of Pathological Complete Response.

Journal: Biomedicines
Published: February 14, 2026

The role of patient age in fertility preservation among women with breast cancer: biological mechanisms and clinical implications.

The role of patient age in fertility preservation among women with breast cancer: biological mechanisms and clinical implications.

Journal: Journal of assisted reproduction and genetics
Published: December 18, 2025

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III.

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III.

Journal: Current oncology (Toronto, Ont.)
Published: December 23, 2024

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.

Journal: Cancers
Published: May 21, 2022

Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.

Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption.

Journal: Breast disease
Published: June 07, 2021

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes.

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes.

Journal: Journal of personalized medicine
Published: August 06, 2020

Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study.

Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study.

Journal: Journal of gastrointestinal cancer
Published: July 07, 2020

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: February 28, 2019

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.

Journal: Oncology letters
Published: June 06, 2018

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.

Journal: Immunotherapy
Published: March 23, 2018

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

Journal: Oncotarget
Published: July 27, 2017

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.

Journal: Oncotarget
Published: November 08, 2016
Showing 1-12 of 13

Last Updated: 09/26/2026